معرفی
Alison M. Michie is a Professor in Molecular Lymphopoiesis at the Paul O'Gorman Leukaemia Research Centre, University of Glasgow. She leads a research group focused on molecular mechanisms of hematopoietic stem cell differentiation into B/T lymphocytes and the pathogenesis of chronic lymphocytic leukemia (CLL). Her work bridges fundamental biology and translational applications, with collaborations across academia (e.g., University of Leicester, University of Edinburgh) and industry (GlaxoSmithKline).
Her research interests center on:
- Molecular events in early B/T cell development
- PKC and mTOR signaling in leukemia
- Oncogenic triggers for CLL
- Therapeutic targeting of leukemic stem cells
- Microenvironmental influences on cancer cell survival
Her recent publications (2019–2025) demonstrate a strong focus on kinase signaling (PKC, mTOR), metabolic reprogramming in leukemia, and epigenetic regulation. Trends include targeting quiescent stem cells, exploiting metabolic vulnerabilities, and developing precision therapies for CLL/AML.
Grants include:
- Medical Research Council (2023–2026): eEF2K/eEF2 signalling in leukemia
- Blood Cancer UK (2019–2021): FOXO regulation in CLL
- Kay Kendall Leukaemia Fund (2014–2018): mTOR in CLL
